Home
Services
About Us
Contact Us

Connecticut-based Contine Corporation takes the win for Mid Atlantic Bio Angels’ 1st Pitch Life Science competition.

March 11, 2014/in News /by Competitive

Continue reading →

Tags: Best in Show, Mid-Atlantic Bio Angels, non-surgical device, stress urinary incontinence

Share this entry

You might also like

Oculogica is named "Best in Show" at the Mid-Atlantic Bio Angels' 1st Pitch Life Science event.

FITSCRIPT wins “Best in Show” award at Mid Atlantic Bio Angels' 1st Pitch Life Science event.

1st Pitch Life Sciences – 5:30 pm on Feb 24th, 2015

Angulus wins Mid-Atlantic Bio Angels' 1st Pitch Life Science competition.

Immunovent is awarded “Best-of-the-Best” designation at Mid Atlantic Bio Angels' 1st Pitch Life Science event.

1st Pitch Life Sciences showcase – 5:30 pm on Dec 10th, 2014.

Search

Tags

1st Pitch Life Sciences angiotensin II type 2 receptor antagonist autoimmune disease Best in Show Big Data biotechnology BoxGroup Brandon Capital Partners Canaan Partners Catalyst Health Ventures chronic pain Connecticut Innovations electronic medical records employee health benefits eye-tracking technology First Round flu GBS Venture Partners Google Ventures Harris & Harris Group infectious disease inflammation Lerer Ventures Mid-Atlantic Bio Angels New Atlantic Ventures New Leaf Venture Partners non-dilutive financing non-surgical device Novo A/S oncology Phase 2 prescription benefits protein degradation SaaS Series A Series B Series C Serious Change stress urinary incontinence Tribeca Venture Partners UniQuest Uniseed vaccine Vaizra Investments ventilator-associated pneumonia

Archive of news

February 2015
January 2015
December 2014
November 2014
October 2014
July 2014
June 2014
May 2014
April 2014
March 2014
January 2014
December 2013
September 2013

© 2015 All rights reserved - Drevo Analytics, LLC

Accessibility
Credits
Privacy Policy
Terms of Use

VaxInnate, a biotechnology company developing novel anti-flu vaccines, is selected...

Spinifex Pharmaceuticals, a pain drug development company, raises $45MM in Series...

Scroll to top